Iron Patents (Class 514/502)
-
Publication number: 20120093898Abstract: A composition containing a plurality of water-soluble nanoclusters ranging from 2 nm to 500 nm in diameter. Each of the nanoclusters contains one or more metal cations, one or more anions, and one or more water-soluble ligands. Also disclosed is a method of using the composition for treating various disorders such as anemia, heartburn, and diabetes.Type: ApplicationFiled: November 18, 2010Publication date: April 19, 2012Applicant: LG Bionano, LLCInventor: Chien-Chin Wu
-
Publication number: 20120093910Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.Type: ApplicationFiled: December 23, 2011Publication date: April 19, 2012Inventors: Brij SAXENA, Mukul Singh, Sidney Lerner
-
Publication number: 20120039969Abstract: A novel dosage form. The dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active substances, the vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a time period of 5 minutes or less swells and/or gels and the texture of the swelled vehicle being similar to that of a soft pudding and having a viscosity of at least about 10,000 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25° C.Type: ApplicationFiled: August 18, 2011Publication date: February 16, 2012Inventors: Daniel Bar-Shalom, Lillian Slot, Gina Fischer, Pernille Hoyrup Hemmingsen
-
Publication number: 20120027832Abstract: A molluscicidal composition, comprising: a molluscicide; a molluscicidal activity promoting additive comprising a calcium-containing salt of ethylene disuccinic acid or calcium ions and ethylenediamine disuccinic moieties, having at least 1 mole of calcium per mole of ethylenediamine disuccinic acid; and a carrier material edible to molluscs.Type: ApplicationFiled: January 26, 2010Publication date: February 2, 2012Inventors: Nicholas John Dixon, Derek Bassett, Reinhard Arndt, Andreas Prokop, Diana Parker, Tianye Chen
-
Publication number: 20120021010Abstract: Disclosed herein are compositions and methods for inhibiting platelet aggregation in a patient in need thereof. The compositions and methods use superparamagnetic iron oxide nanoparticles (SPIONs), which are shown to inhibit aggregation of platelets. Such methods are useful in preventing blood clotting in diseases such as acute coronary syndrome. Also disclosed are in vitro methods of sensing platelet function using SPIONs.Type: ApplicationFiled: June 14, 2010Publication date: January 26, 2012Inventors: Suryyani Deb, Anjan Kr. Dasgupta
-
Publication number: 20120010213Abstract: Disclosed herein is an oral controlled release pharmaceutical formulation comprising water-soluble drug or pharmaceutically acceptable salts thereof, in a hydrophilic matrix system, further comprising pH independent polymers present in an amount of 5% to 90% w/w in combination with acid insoluble polymer present in an amount of 1% to 70% w/w and/or a diluent, a lubricant and/or a glidant.Type: ApplicationFiled: September 6, 2011Publication date: January 12, 2012Applicant: FDC LIMITEDInventors: Mohan Anand CHANDAVARKAR, Kour Chand Jindal, Rajkumar Malayandi
-
Patent number: 8093423Abstract: The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.Type: GrantFiled: August 18, 2006Date of Patent: January 10, 2012Assignee: GloboAsia, LLCInventors: Keith Chan, Winston Town
-
Patent number: 8080520Abstract: A composition comprising heme iron and/or heme iron polypeptide in combination with ionic iron(s) and/or chelated iron(s). Administration of effective dosages of the present composition provides a method for treating and/or preventing iron deficiency anemia, and the physiological, biochemical, morphological, and behavioral manifestations symptomatic of same.Type: GrantFiled: July 20, 2009Date of Patent: December 20, 2011Inventors: Bala Venkataraman, Michael Guthrie
-
Patent number: 8067628Abstract: The present invention relates to water-soluble binuclear cationic nitrosyl iron complexes with natural aliphatic thiolyls of general formula [Fe2(SR)2(NO)4]SO4, wherein R is sulfur-containing aliphatic ligands of natural origin, preferably, cystamine or penicillamine, to a method for the preparation thereof, to use thereof as an anticancer agent, to an apoptosis inducer, to a pharmaceutical composition comprising said complexes in an effective amount, and to a kit useful for the treatment of cancer diseases.Type: GrantFiled: June 2, 2008Date of Patent: November 29, 2011Assignee: Institute of Problems of Chemcial Physics RAS (IPCP RAS)Inventors: Natalia Alexeevna Sanina, Konstantin Alexandrovich Lysenko, Olga Stepanovna Zhukova, Tatyana Nikolaevna Rudneva, Nina Sergeevna Emelianova, Sergei Mikhailovich Aldoshin
-
Publication number: 20110288162Abstract: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thio-hydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof.Type: ApplicationFiled: October 21, 2009Publication date: November 24, 2011Applicant: SYNTA PHARMACEUTICAL CORPInventors: Nagai Masazumi, Jianhua Shen
-
Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation
Patent number: 8058462Abstract: Ligand-modified poly oxo-hydroxy metal ion materials and their uses are disclosed, in particular for nutritional, medical, cosmetic or biologically related applications for example for the treatment of a deficiency related to a component of the material or for the removal of an endogenous substance capable of binding to the material. The present invention further relates to processes for preparing the materials and optimising their physico-chemical properties and their medical uses.Type: GrantFiled: February 6, 2008Date of Patent: November 15, 2011Assignee: Medical Research CouncilInventors: Jonathan Joseph Powell, Sylvaine Francoise Bruggraber, Nuno Jorge Rodrigues Faria, Dora Isabel Amaral Pereira -
Patent number: 8053470Abstract: The invention discloses a process for preparing a polynuclear ferric hydroxide-saccharide complex, including: adding an aqueous solution of an alkaline substance drop-wise into an aqueous solution of iron salt at a temperature of 5-20° C. until pH 6-8, collecting the polynuclear ferric hydroxide from the reaction mixture by a conventional method; reacting the polynuclear ferric hydroxide with a saccharide in a solution of an alkaline substance for 10-40 hours at 106-125° C. under pH 10-12, resulting in a crude product having an isoelectric point of 4.4-5.3 and a weight average molecular weight of 20,000-100,000 Daltons, and then harvesting the polynuclear ferric hydroxide-saccharide complex from the crude product. The process can precisely control the molecular weight of the polynuclear ferric hydroxide-saccharide complex without an effect on the other characteristics of the product, for example its saccharide content or isoelectric point etc. Furthermore, it is very simple and readily applicable in industry.Type: GrantFiled: April 12, 2006Date of Patent: November 8, 2011Assignee: Chongqing Pharmaceutical Research Institute Co., Ltd.Inventors: Jinmai Xiao, Jie Deng, Jinhua Feng, Bo Xiao
-
Patent number: 8007853Abstract: Compositions containing the fatty acid docosahexaenoic acid (DHA) in combination with at least one vitamin and mineral are provided to supplement nutrition in a mammalian diet. DHA is present in the composition in concentrated amounts, advantageously in a carrier such as marinol oil, to allow for quantities of DHA sufficient to supply expectant and new mothers and their children as recommended on a daily basis. This DHA may also be used to treat a variety of disorders in children and adults. The compositions advantageously include vitamins, minerals, and optionally other nutrients to provide a nutritional supplement which may be convenient to swallow and taken once a day.Type: GrantFiled: April 21, 2010Date of Patent: August 30, 2011Assignee: Xanodyne Pharmaceuticals, Inc.Inventors: Roland J. Bydlon, William R. Hurd, Prasad Nidamarty
-
Publication number: 20110206781Abstract: Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells (HSC) and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro, ex vivo and/or in vivo. Also described are methods, compositions and kits related to making an expanded population of HSC and methods, compositions and kits related to using the expanded population of HSC. For example, HSC growth may be enhanced by contacting the nascent stem cells or HSC with an agent that stimulates the nitric oxide signaling pathway.Type: ApplicationFiled: May 28, 2009Publication date: August 25, 2011Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Publication number: 20110196033Abstract: It is to provide a pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease; and a method for preventing/treating an adult disease by using the same.Type: ApplicationFiled: October 27, 2009Publication date: August 11, 2011Applicant: SBI ALAPROMO CO., LTD.Inventor: Tohru Tanaka
-
Patent number: 7994217Abstract: Multivitamin/Multimineral supplements are provided for supplementing iron and desirable nutrients in the diet of mammals. The supplements include an iron-amino acid chelate, a form of iron more bioavailable than traditional iron salts. The supplements may further include a pharmaceutically accepted salt form of iron as well as other nutritional vitamins and minerals. The supplements are useful for providing iron for pregnant and lactating females as well as for persons suffering from anemia.Type: GrantFiled: February 27, 2003Date of Patent: August 9, 2011Assignee: Xanodyne Pharmaceuticals, Inc.Inventors: Prasad Nidamarty, William R. Hurd, Roland J. Bydlon, William C. Williams, Michael Dempsey, Amy Erbskorn
-
Publication number: 20110190391Abstract: The present invention relates to compounds of the following formula (I): and to the pharmaceutically acceptable salts thereof, to the isomers and the mixtures of isomers thereof and to the water-soluble derivatives thereof, as well as to the method for preparing same and to the use thereof, particularly in the treatment of cancer.Type: ApplicationFiled: July 2, 2009Publication date: August 4, 2011Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Gérard Jaouen, Anne Vessieres-Jaouen, Damian Plazuk
-
Patent number: 7989650Abstract: Metal carbonyls are used to deliver CO to organs to limit post-ischaemic damage. The organ may be extracorporeal, e.g. for use in a transplant, or may be an isolated organ inside or attached to the body but isolated from the blood flow. The carbonyl preferably has one or more other ligands other than CO, such as amino acids, to modulate the CO release property and solubility.Type: GrantFiled: November 20, 2003Date of Patent: August 2, 2011Assignee: hemoCORM LimitedInventors: Roberto Angelo Motterlini, Brian Ernest Mann
-
Patent number: 7988950Abstract: The present invention relates to a novel class of paramagnetic ion-based contrast i agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhydroxylated chain, that show a pharmacokinetic i profile analogous to that of the commonly used T1-general extravascular agents (NSA) but are further characterized by a higher relaxivity.Type: GrantFiled: June 28, 2005Date of Patent: August 2, 2011Assignee: Bracco Imaging S.p.A.Inventors: Silvio Aime, Matteo Galli, Luciano Lattuada, Pierfrancesco Morosini, Fulvio Uggeri, Kondareddiar Ramalingam
-
Publication number: 20110171187Abstract: The present invention provides a dietary supplement that promote the growth, repair, and maintenance of mammalian bone and joint connective tissue. In particular, the dietary supplement comprises a combination of at least one metal chelate and at least one chondroprotective agent.Type: ApplicationFiled: May 30, 2008Publication date: July 14, 2011Applicant: Novus International, Inc.Inventors: Jeremy D. Moore, Thomas R. Hampton, Robert Harrell
-
Patent number: 7964568Abstract: A process for preparing parenteral iron-saccharidic complexes, and the complexes produced, comprising: (1) providing an aqueous solution or dispersion including (i) Fe(III) and (OH)? ions and (ii) at least one saccharide, to form a reaction mixture, where the molar ratio of (i): (ii) is about 30:1 to about 1:30; and the mixture temperature and pH are at or above the complex assembly point (CAP); and (2) maintaining temperature and pH at or above the CAP for a time sufficient to form an iron-saccharidic complex having a molecular weight of about 25,000 Daltons or more. Control of the temperature and pH efficiently produces a high molecular weight complex. The complex can be separated by precipitation, dialysis and/or column fractionation and, if desired, dried, e.g., lyophilized or spray dried. The process can controllably synthesize complexes of varying molecular weight and/or chemical composition, particularly sodium ferric gluconate and ferric hydroxide-sucrose.Type: GrantFiled: May 26, 2004Date of Patent: June 21, 2011Assignee: Chromaceutical Advanced Technologies, Inc.Inventors: Robert A. Beck, Robert A. Mateer, Jr., John Kowalski
-
Patent number: 7964205Abstract: Bait compositions of spinosyns in combination with metal complexones and other mollusicides are provided in an environmentally safe composition that is effective to a treat and/or control a wide spectrum of insect and mollusc pests.Type: GrantFiled: September 13, 2006Date of Patent: June 21, 2011Assignee: W. Neudorff GmbH KGInventors: Diana L. Parker, Cameron D. Wilson, George S. Puritch, David S. Almond
-
Patent number: 7943664Abstract: Phosphate binding materials and compositions comprising them which are solid ligand-modified poly oxo-hydroxy metal ion materials are disclosed that are based on ferric iron oxo-hydroxides modified with carboxylic acid ligands, or ionized forms thereof. These materials are made and tested in the examples provided in the application to demonstrate that they can bind phosphate in in vitro and in in vivo studies.Type: GrantFiled: August 5, 2009Date of Patent: May 17, 2011Assignee: Medical Research CouncilInventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria
-
Publication number: 20110104308Abstract: Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx/Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine.Type: ApplicationFiled: May 7, 2009Publication date: May 5, 2011Applicant: DUKE UNIVERSITYInventors: Jonathan S. Stamler, Moran Benhar
-
Publication number: 20110105419Abstract: The invention relates to the use of small and ultra small quantities of bi- and oligo-nuclear forms of the coordination compounds of d-metals in the form of drugs or agents for enhancing the therapeutic efficiency of pharmacological substances.Type: ApplicationFiled: February 16, 2009Publication date: May 5, 2011Inventors: Mark Borisovich Balazovsky, Viktor Georgievich Antonov, Alexandr Nikolaevich Belayev, Alexei Viktorovich Eremin
-
Publication number: 20110091383Abstract: Synthetic peptidomimetic derivatives and phenyl group derivatives of Fenretinide (4-HPR) are disclosed, as are their uses as therapeutic, diagnostic and imaging agents for cancer and other diseases.Type: ApplicationFiled: March 11, 2009Publication date: April 21, 2011Inventors: Ganjam V. Kalpana, Bhaskar C. Das
-
Publication number: 20110081425Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.Type: ApplicationFiled: December 14, 2010Publication date: April 7, 2011Applicant: W. NEUDORFF GMBH KGInventor: Diana L. Parker
-
Patent number: 7910137Abstract: Metal carnitine chelates comprising carnitine chelated to a nutritionally relevant metal can be used for general nutrition as well as well as to treat a variety of health related problems and symptoms. For example, metal carnitine chelates can be used to maintain good cardiovascular health, increase male fertility, enhance weight loss, provide mineral and/or carnitine supplements for mineral- and/or carnitine-deficient subjects, and reduce alcohol dependency and associated symptoms. Nutritionally relevant metals that can be used include copper, zinc, magnesium, calcium, iron, chromium, and manganese, to name a few.Type: GrantFiled: July 7, 2006Date of Patent: March 22, 2011Assignee: Albion International, Inc.Inventors: H. DeWayne Ashmead, R. Charles Thompson
-
Publication number: 20110065787Abstract: The present invention is intended to provide an agent for treating male infertility which is highly effective to male infertility, and having few side effects. To achieve the object, an agent for treating male infertility comprising ?-amino levulinic acid shown by general formula (1), its derivative or salt thereof: R2R1NCH2COCH2CH2COR3??(1) [wherein R1 and R2 independently represent a hydrogen atom, alkyl group, acyl group, alkoxycarbonyl group, aryl group, or aralkyl group; R3 represents a hydroxy group, alkoxy group, acyloxy group, alkoxycarbonyloxy group, aryloxy group, aralkyloxy group or amino group] can be used.Type: ApplicationFiled: May 13, 2009Publication date: March 17, 2011Inventors: Setsuko Miyanari, Masumi Takahashi, Masahiro Ishizuka, Tohru Tanaka
-
Publication number: 20110060041Abstract: The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.Type: ApplicationFiled: June 22, 2010Publication date: March 10, 2011Inventors: Chen Hsing Hsu, Shou Shan Chiang
-
Publication number: 20110060042Abstract: The present invention provides an external preparation for skin which contains 5-aminolevulinic acids as active components and which is excellent in skin-beautifying effects such as prevention/amelioration of skin roughness, dry skin, wrinkles, sagging and flecks of skin, and improvement of turnover of corneum; and in an ameliorating effect on skin diseases such as atopic dermatitis. An external preparation for skin which contains one or more compounds selected from the group consisting of 5-aminolevulinic acid, its salt and a derivative of them; and an iron compound; as active components, is used.Type: ApplicationFiled: November 12, 2010Publication date: March 10, 2011Applicant: SBI ALApromo Co., Ltd.Inventor: Yoshiyasu Ito
-
Publication number: 20110054019Abstract: The present invention is a glutamine analogue which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.Type: ApplicationFiled: September 1, 2009Publication date: March 3, 2011Inventor: Pedro Anastacio Serrano-Ojeda
-
Publication number: 20110039927Abstract: The invention relates to compositions and processes for producing novel hop acid formulations having improved bioavailability, and the use of such compositions as anti-inflammatory agents, dietary supplements, and pharmaceuticals.Type: ApplicationFiled: June 21, 2006Publication date: February 17, 2011Inventors: Kevin K. Madsen, Mark M. Bossert, Mitsunori Ono
-
Patent number: 7883897Abstract: A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals.Type: GrantFiled: February 25, 2010Date of Patent: February 8, 2011Assignee: Chromaceutical Advanced Technologies, Inc.Inventors: Robert A. Beck, Robert A. Mateer, Jr.
-
Publication number: 20110021629Abstract: New iron preparations comprising stable, unpolymerized iron(III) citrate complex compositions and methods for their preparation are provided. Further, the invention involves the use stable, unpolymerized iron(III) citrate complex compositions of the invention as a food additive, nutritional supplement, dietary supplement, medical food, nutrient, iron fortificant, and source of iron in the fields of nutrition for humans, animals, fish, and birds and of diagnostics. The invention further involves the use of stable, unpolymerized iron(III) citrate complex compositions of the invention as a pharmaceutical and pharmacologically active ingredient for human clinical and veterinary applications.Type: ApplicationFiled: July 21, 2009Publication date: January 27, 2011Inventors: Deanna Jean Nelson, Brian J. Mosley
-
Publication number: 20110021461Abstract: The present invention provides combinations of dietary supplements and methods of using of these combinations to improve the health and production performance of animals. In particular, the combinations of the invention comprise antioxidants, trace minerals, organic acids, essential amino acids, and mixtures thereof.Type: ApplicationFiled: December 30, 2008Publication date: January 27, 2011Applicant: NOVUS INTERNATIONAL INC.Inventors: Mercedes Vazquez-Anon, Gavin Bowman, Steven Andrew Webb, James Richards, Robert Harrell, Junmei Zhao, Megharaja K. Manangi
-
Publication number: 20110015263Abstract: Compounds, pharmaceutical compositions and methods for the therapeutic delivery of carbon monoxide to humans and other mammals that employ transition metal complexes having at least a substituted cyclopentadienyl, indenyl or fluorenyl ligand and two or more carbonyl ligands.Type: ApplicationFiled: January 23, 2007Publication date: January 20, 2011Inventors: Roberto Angelo Motterlini, Brian Ernest Mann, Tony Richard Johnson, David Alistair Scapens, Rehan Aqil, Trevor Perrior
-
Publication number: 20110014256Abstract: A long-lasting anti-microbial composition is provided, which includes one or more polymer or oligomer and a plurality of nanowires distributed therein, wherein the nanowires have an aspect ratio of more than 20 and the nanowires form a network-like structure. An anti-microbial film and spray including the composition are also provided.Type: ApplicationFiled: April 5, 2010Publication date: January 20, 2011Inventors: Ling-Ko CHANG, Yu-Ming Wang, Kao-Der Chang, Wen-Hsien Sun, Ming-Jyh Chang
-
Publication number: 20100273763Abstract: This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.Type: ApplicationFiled: November 30, 2007Publication date: October 28, 2010Applicants: Women & Infants Hospital, Louisiana State UniversityInventors: Laurent Brard, Rakesh Singh, Satyan Kalkunte, Robert Strongin, Onur Alpturk
-
Patent number: 7816404Abstract: A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.Type: GrantFiled: June 12, 2008Date of Patent: October 19, 2010Assignee: Rockwell Medical Technologies, Inc.Inventor: William S. McCall, Jr.
-
Publication number: 20100260676Abstract: A method of preparing multifunctionalized nanoparticles involves using a modular system of half-linkers to attach functional moieties that serve to deliver the nanoparticles to a desired target, exert an effect at the target, or track the nanoparticles within a cell or an animal. The modular chemistry of the half-linker system permits the custom design and synthesis of functionalized nanoparticles bearing multiple groups and therefore results in precise delivery to desired cell types and intracellular locations. The functionalized nanoparticles can be used to treat or diagnose a variety of medical conditions, including neoplastic diseases, infectious diseases, and chronic diseases.Type: ApplicationFiled: February 11, 2008Publication date: October 14, 2010Applicant: NORTHEASTERN UNIVERSITYInventors: Robert N. Hanson, Mansoor Amiji, Volkmar Weissig
-
Publication number: 20100247454Abstract: The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.Type: ApplicationFiled: January 12, 2010Publication date: September 30, 2010Inventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek, Severa Bunda
-
Patent number: 7767851Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.Type: GrantFiled: August 18, 2005Date of Patent: August 3, 2010Assignee: Panion & BF Biotech, Inc.Inventors: David W. K. Kwok, Nikolay Mintchev Stoynov
-
Publication number: 20100190850Abstract: The present invention relates to water-soluble binuclear cationic nitrosyl iron complexes with natural aliphatic thiolyls of general formula [Fe2(SR)2(NO)4]SO4, wherein R is sulfur-containing aliphatic ligands of natural origin, preferably, cystamine or penicillamine, to a method for the preparation thereof, to use thereof as an anticancer agent, to an apoptosis inducer, to a pharmaceutical composition comprising said complexes in an effective amount, and to a kit useful for the treatment of cancer diseases.Type: ApplicationFiled: June 2, 2008Publication date: July 29, 2010Applicant: Institute Of Problems of Chemical Physics RAS (IPCP RAS)Inventors: Natalia Alexeevna Sanina, Konstantin Alexandrovich Lysenko, Olga Stepanovna Zhukova, Tatyana Nikolaevna Rudneva, Nina Sergeevna Emelianova, Sergei Mikhailovich Aldoshin
-
Publication number: 20100152131Abstract: A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals.Type: ApplicationFiled: February 25, 2010Publication date: June 17, 2010Applicant: CHROMACEUTICAL ADVANCED TECHNOLOGIES, INC.Inventors: Robert A. Beck, Robert A. Mateer, JR.
-
Publication number: 20100135950Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.Type: ApplicationFiled: June 25, 2007Publication date: June 3, 2010Applicant: Genzyme CorporationInventors: Chad Huval, Pradeep Dhal, Stephen Randall Holmes-Farley
-
Publication number: 20100119608Abstract: Among natural mechanisms of cell deaths, disease or toxicity, one of the most common method is through overloading of certain biological metals such as calcium, iron and zinc. We propose to utilize this natural mechanism of cell death against cancer by utilizing the well known phenomenon of enhanced permeation and retention effect (EPR effect) and metal-binding nanoparticle moieties that can self-degrade under certain biological conditions such as pH. More specifically, we show that one can form nanoparticles that consist of polymerized citric acid and various different types of metals including, but not limited to, iron, calcium, zinc, silver and magnesium, displaying acid-stability and self-degradation leading to constituent metal release when pH rises closer to the neutral pH of 7 or higher.Type: ApplicationFiled: November 11, 2008Publication date: May 13, 2010Inventor: Jinhyuk Fred Chung
-
Patent number: 7704542Abstract: Compositions containing the fatty acid docosahexaenoic acid (DHA) in combination with at least one vitamin and mineral are provided to supplement nutrition in a mammalian diet. DHA is present in the composition in concentrated amounts, advantageously in a carrier such as marinol oil, to allow for quantities of DHA sufficient to supply expectant and new mothers and their children as recommended on a daily basis. This DHA may also be used to treat a variety of disorders in children and adults. The compositions advantageously include vitamins, minerals, and optionally other nutrients to provide a nutritional supplement which may be convenient to swallow and taken once a day.Type: GrantFiled: September 12, 2002Date of Patent: April 27, 2010Assignee: Xanodyne Pharmaceuticals, Inc.Inventors: Roland J. Bydlon, William R. Hurd, Prasad Nidamarty
-
Patent number: 7687273Abstract: A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals.Type: GrantFiled: July 7, 2005Date of Patent: March 30, 2010Assignee: Chromaceutical Advanced Technologies, Inc.Inventors: Robert A. Beck, Robert A. Mateer, Jr.
-
Publication number: 20100062039Abstract: This invention generally covers a ringed-mesh intravaginal device and applicator therefore wherein the ringed-mesh comprises a composite ring comprising a flexible matrix containing one or more bioactive agent or agents and needed excipients or modulators, and the said matrix is reinforced with a fibrous construct to provided needed initial and in-use biomechanical stability. Of special application of the medicated, ringed-mesh is its use for securing contraception relying on biomechanical, pharmacological, and biochemical means.Type: ApplicationFiled: December 14, 2005Publication date: March 11, 2010Inventor: Shalaby W. Shalaby